Cargando…

Tricyclic antidepressants and headaches: systematic review and meta-analysis

Objective To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches. Design Meta-analysis. Data sources Medline, Embase, the Cochrane Trials Registry, and PsycLIT. Studies reviewed Randomised trials of adults re...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Jeffrey L, Shimeall, William, Sessums, Laura, DeZee, Kent J, Becher, Dorothy, Diemer, Margretta, Berbano, Elizabeth, O’Malley, Patrick G
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958257/
https://www.ncbi.nlm.nih.gov/pubmed/20961988
http://dx.doi.org/10.1136/bmj.c5222
_version_ 1782188311947771904
author Jackson, Jeffrey L
Shimeall, William
Sessums, Laura
DeZee, Kent J
Becher, Dorothy
Diemer, Margretta
Berbano, Elizabeth
O’Malley, Patrick G
author_facet Jackson, Jeffrey L
Shimeall, William
Sessums, Laura
DeZee, Kent J
Becher, Dorothy
Diemer, Margretta
Berbano, Elizabeth
O’Malley, Patrick G
author_sort Jackson, Jeffrey L
collection PubMed
description Objective To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches. Design Meta-analysis. Data sources Medline, Embase, the Cochrane Trials Registry, and PsycLIT. Studies reviewed Randomised trials of adults receiving tricyclics as only treatment for a minimum of four weeks. Data extraction Frequency of headaches (number of headache attacks for migraine and number of days with headache for tension-type headaches), intensity of headache, and headache index. Results 37 studies met the inclusion criteria. Tricyclics significantly reduced the number of days with tension-type headache and number of headache attacks from migraine than placebo (average standardised mean difference −1.29, 95% confidence interval −2.18 to −0.39 and −0.70, −0.93 to −0.48) but not compared with selective serotonin reuptake inhibitors (−0.80, −2.63 to 0.02 and −0.20, −0.60 to 0.19). The effect of tricyclics increased with longer duration of treatment (β=−0.11, 95% confidence interval −0.63 to −0.15; P<0.0005). Tricyclics were also more likely to reduce the intensity of headaches by at least 50% than either placebo (tension-type: relative risk 1.41, 95% confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to 2.62) or selective serotonin reuptake inhibitors (1.73, 1.34 to 2.22 and 1.72, 1.15 to 2.55). Tricyclics were more likely to cause adverse effects than placebo (1.53, 95% confidence interval 1.11 to 2.12) and selective serotonin reuptake inhibitors (2.22, 1.52 to 3.32), including dry mouth (P<0.0005 for both), drowsiness (P<0.0005 for both), and weight gain (P<0.001 for both), but did not increase dropout rates (placebo: 1.22, 0.83 to 1.80, selective serotonin reuptake inhibitors: 1.16, 0.81 to 2.97). Conclusions Tricyclic antidepressants are effective in preventing migraine and tension-type headaches and are more effective than selective serotonin reuptake inhibitors, although with greater adverse effects. The effectiveness of tricyclics seems to increase over time.
format Text
id pubmed-2958257
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-29582572010-10-28 Tricyclic antidepressants and headaches: systematic review and meta-analysis Jackson, Jeffrey L Shimeall, William Sessums, Laura DeZee, Kent J Becher, Dorothy Diemer, Margretta Berbano, Elizabeth O’Malley, Patrick G BMJ Research Objective To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches. Design Meta-analysis. Data sources Medline, Embase, the Cochrane Trials Registry, and PsycLIT. Studies reviewed Randomised trials of adults receiving tricyclics as only treatment for a minimum of four weeks. Data extraction Frequency of headaches (number of headache attacks for migraine and number of days with headache for tension-type headaches), intensity of headache, and headache index. Results 37 studies met the inclusion criteria. Tricyclics significantly reduced the number of days with tension-type headache and number of headache attacks from migraine than placebo (average standardised mean difference −1.29, 95% confidence interval −2.18 to −0.39 and −0.70, −0.93 to −0.48) but not compared with selective serotonin reuptake inhibitors (−0.80, −2.63 to 0.02 and −0.20, −0.60 to 0.19). The effect of tricyclics increased with longer duration of treatment (β=−0.11, 95% confidence interval −0.63 to −0.15; P<0.0005). Tricyclics were also more likely to reduce the intensity of headaches by at least 50% than either placebo (tension-type: relative risk 1.41, 95% confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to 2.62) or selective serotonin reuptake inhibitors (1.73, 1.34 to 2.22 and 1.72, 1.15 to 2.55). Tricyclics were more likely to cause adverse effects than placebo (1.53, 95% confidence interval 1.11 to 2.12) and selective serotonin reuptake inhibitors (2.22, 1.52 to 3.32), including dry mouth (P<0.0005 for both), drowsiness (P<0.0005 for both), and weight gain (P<0.001 for both), but did not increase dropout rates (placebo: 1.22, 0.83 to 1.80, selective serotonin reuptake inhibitors: 1.16, 0.81 to 2.97). Conclusions Tricyclic antidepressants are effective in preventing migraine and tension-type headaches and are more effective than selective serotonin reuptake inhibitors, although with greater adverse effects. The effectiveness of tricyclics seems to increase over time. BMJ Publishing Group Ltd. 2010-10-20 /pmc/articles/PMC2958257/ /pubmed/20961988 http://dx.doi.org/10.1136/bmj.c5222 Text en © Jackson et al 2010 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Research
Jackson, Jeffrey L
Shimeall, William
Sessums, Laura
DeZee, Kent J
Becher, Dorothy
Diemer, Margretta
Berbano, Elizabeth
O’Malley, Patrick G
Tricyclic antidepressants and headaches: systematic review and meta-analysis
title Tricyclic antidepressants and headaches: systematic review and meta-analysis
title_full Tricyclic antidepressants and headaches: systematic review and meta-analysis
title_fullStr Tricyclic antidepressants and headaches: systematic review and meta-analysis
title_full_unstemmed Tricyclic antidepressants and headaches: systematic review and meta-analysis
title_short Tricyclic antidepressants and headaches: systematic review and meta-analysis
title_sort tricyclic antidepressants and headaches: systematic review and meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958257/
https://www.ncbi.nlm.nih.gov/pubmed/20961988
http://dx.doi.org/10.1136/bmj.c5222
work_keys_str_mv AT jacksonjeffreyl tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis
AT shimeallwilliam tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis
AT sessumslaura tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis
AT dezeekentj tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis
AT becherdorothy tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis
AT diemermargretta tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis
AT berbanoelizabeth tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis
AT omalleypatrickg tricyclicantidepressantsandheadachessystematicreviewandmetaanalysis